The EEG profile in responders to methylphenidate will be differ from the EEG profile in non-responders to methylphenidate (i.e. higher total power, increased theta/beta ratio and theta/alpha ratio).
ID
Bron
Verkorte titel
Aandoening
ADHD, methylphenidate response, EEG, DNA, CANTAB, spatial span, spatial working memory, stop-task, CPT, theta/beta ratio
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Primary outcome measure is the absolute and relative power in different frequency bands of the EEG.
Achtergrond van het onderzoek
Approximately 3 to 5 % of the children is diagnosed with ADHD. ADHD is mostly treated with methylphenidate. However 30 % of the children with ADHD does not respond to methylphenidate. At this moment there is no objective tool available to predict methylphenidate response. It would be of great value to have an objective tool. EEG power measures, ERPs, neuropsychological tests, and DNA all seem to have some predictive value with regard to methylphenidate response. The aim of the present study is to investigate the predictive value of EEG power by studying EEG power differences between responders and non-responders to methylphenidate. Furthermore, the predictive value of EEG power measures will be compared with the predictive value of DNA, neuropsychological tests and ERPs. Brain activity, DNA, and task performance (stop-task, CPT, Spatial Span task, Spatial Working Memory Task) will be measured in methylphenidate-naive patients in a baseline condition and after treatment administration (10 mg methylphenidate).
Doel van het onderzoek
The EEG profile in responders to methylphenidate will be differ from the EEG profile in non-responders to methylphenidate (i.e. higher total power, increased theta/beta ratio and theta/alpha ratio).
Onderzoeksopzet
N/A
Onderzoeksproduct en/of interventie
Methylphenidate 10 mg.
Algemeen / deelnemers
A.E. Wester
Sorbonnelaan 16
Utrecht 3584 CA
The Netherlands
+31(0)302537768
A.E.Wester@uu.nl
Wetenschappers
A.E. Wester
Sorbonnelaan 16
Utrecht 3584 CA
The Netherlands
+31(0)302537768
A.E.Wester@uu.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Diagnosed with ADHD combined type (no primary diagnoses of attention deficit) according to DSM IV criteria (DSM IV, APA
1994);
2. They have (no history of) anxiety disorder, depression, tics, psychosis or autism;
3. Their age is ranged between 7 and 12;
4. IQ is above 75;
5. They are free from psychoactive
medication;
6. They are free from methylphenidate at least 48 hours before testing;
7. They have no known cardiovascular disease;
8. Normal static binocular acuity, corrected or uncorrected;
9. Written informed consent from the parents.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. IQ is below 75;
2. One or more of the following comorbid disorders are diagnosed: anxiety disorder,
depression, tics, psychosis or autism;
3. Prior enrolment in the same study;
4. Participation in another clinical trial
simultaneously;
5. Familiar with epileptic disorders;
6. Long term usage of methylphenidate (> 3 months).
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL969 |
| NTR-old | NTR996 |
| Ander register | : P06-160C |
| ISRCTN | ISRCTN32841168 |